The reiteration of the Outperform rating and maintenance of the $8 price target by Oppenheimer analyst Leland Gershell indicates a positive outlook for Soleno Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's performance and potential growth.